MediaAlpha: Okami Medical Receives FDA Clearance for SENDERO MAX Delivery Catheter Expansion
- Okami Medical receives FDA clearance for SENDERO MAX Delivery Catheter, enhancing its embolization portfolio.
- The SENDERO MAX features advanced design elements for improved usability in vascular interventions.
- Okami Medical is supported by industry professionals and venture capital, focusing on innovative medical device solutions.
Okami Medical Expands Embolization Portfolio with FDA Clearance for SENDERO MAX Delivery Catheter
Okami Medical, a California-based company specializing in medical devices for vascular interventions, recently announces it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its SENDERO MAX Delivery Catheter. This new device enhances Okami's embolization portfolio, which already features the SENDERO Microcatheter and LOBO® occluders. Designed to obstruct blood flow in peripheral arterial vessels ranging from 1.5mm to 9.0mm, the SENDERO MAX aims to provide interventional radiologists with an effective tool for managing vascular conditions.
The SENDERO MAX Delivery Catheter integrates advanced features to improve the clinical experience for both physicians and patients. It incorporates a hydrophilic coating and a stainless steel braid, which enhances trackability and facilitates the precise placement of interventional devices. Additionally, a radiopaque marker band allows for better visibility during procedures. The device also boasts a lubricious PTFE inner liner, ensuring low-friction delivery. These elements collectively enhance the catheter's usability, making it a valuable addition to the existing LOBO occluders that utilize the patented HDBRAID® technology for efficient vessel occlusion.
Rhonda Robb, President and CEO of Okami Medical, expresses her enthusiasm regarding the SENDERO MAX, highlighting that it empowers physicians to treat patients more effectively. By expanding their catheter portfolio, Okami continues to address the evolving medical needs within the vascular domain. Dr. Nima Kokabi, an Interventional Radiologist, supports this sentiment, noting that the SENDERO and LOBO combination offers enhanced capabilities that surpass traditional embolization methods. As Okami Medical works to innovate in the field of peripheral vessel occlusion, its commitment to developing comprehensive solutions remains evident.
In addition to its recent FDA approval, Okami Medical is backed by experienced industry professionals and venture capital investments from firms like Vensana Capital and U.S. Venture Partners (USVP). Established in 2017 by Inceptus Medical, the company is dedicated to creating innovative devices that meet the demands of modern healthcare. For further information about the SENDERO MAX and other products, Okami Medical's website provides comprehensive resources and insights into their offerings.